Abrogation of resistance against bevacizumab (Bev) by mitochondrial inhibition: A phase 0 randomized trial of Bev plus ME344 or placebo in early HER2-negative breast cancer (HERNEBC).

被引：4
|
作者：
Quintela-Fandino, Miguel
Apala, Juan V.
Salgado, Alfonso Cortes
Mouron, Silvana Andrea
Guerra, Juan Antonio
Cortes, Mana Gion
Morente, Manuel
Manso, Luis
机构：
[1] CNIO Spanish Natl Canc Res Ctr, Madrid, Spain
[2] CNIO, Madrid, Spain
[3] Hosp Ramon & Cajal, Madrid, Spain
[4] Spanish Natl Canc Res CNIO, Breast Canc Clin Res Unit, Madrid, Spain
[5] Hosp Fuenlabrada, Madrid, Spain
[6] Hosp 12 Octubre, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.2552
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2552
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Hand-foot-syndrome (HFS) is a strong predictor for OS and PFS in HER2-negative metastatic breast cancer (mBC) treated with first-line capecitabine (CAP) plus bevacizumab (BEV): Results of a subanalysis of the randomized phase III CECOG TURANDOT trial
    Christoph, Zielinski C.
    Istvan, Lang
    Semir, Beslija
    Zsuzsanna, Kahan
    Inbar, Moshe J.
    Salomon, Stemmer M.
    Rodica, Anghel
    Damir, Vrbanec
    Diethelm, Messinger
    Thomas, Brodowicz
    CANCER RESEARCH, 2015, 75
  • [22] Real-world effectiveness and safety of first-line bevacizumab (BEV) plus paclitaxel (PAC) in > 2000 patients (pts) with HER2-negative metastatic breast cancer (mBC)
    Mueller, V.
    Dank, M.
    de Ducla, S.
    Mitchell, L.
    Schneeweiss, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [23] Quality of life (QoL) results from the TURANDOT trial comparing two bevacizumab (BEV)-containing regimens as first-line treatment for HER2-negative metastatic breast cancer (mBC)
    Lang, I.
    Inbar, M. J.
    Kahan, Z.
    Greil, R.
    Beslija, S.
    Stemmer, S. M.
    Kaufman, B.
    Ahlers, S.
    Brodowicz, T.
    Zielinski, C.
    CANCER RESEARCH, 2012, 72
  • [24] Femara plus ribociclib or placebo as neoadjuvant endocrine therapy for women with ER+, HER2-negative early breast cancer - The Feline trial
    Khan, Q. J.
    Prochaska, L. H.
    Mohammad, J.
    Yuan, Y.
    O'Dea, A.
    Bardia, A.
    Wisinski, K.
    Hard, M.
    Baccaray, S.
    Makhoul, I.
    Wagner, J.
    Laura, S.
    Ma, C.
    Sharma, P.
    CANCER RESEARCH, 2017, 77
  • [25] First-line bevacizumab plus paclitaxel in Japanese patients with HER2-negative metastatic breast cancer: subgroup results from the randomized Phase III MERiDiAN trial
    Masuda, Norikazu
    Takahashi, Masato
    Nakagami, Kazuhiko
    Okumura, Yasuhiro
    Nakayama, Takahiro
    Sato, Nobuaki
    Kanatani, Kazumitsu
    Tajima, Kosei
    Kashiwaba, Masahiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (05) : 385 - 392
  • [26] Efficacy of first-line bevacizumab (Bev) combined with weekly paclitaxel (wPac) for HER2-negative metastatic breast cancer (MBC): Results of a Japanese phase II study (n=120)
    Ito, Y.
    Aogi, K.
    Masuda, N.
    Ohno, S.
    Oda, T.
    Iwata, H.
    Kashiwaba, M.
    Fujiwara, Y.
    Kamigaki, S.
    Ueno, T.
    Takashima, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
    Miles, D. W.
    de Haas, S. L.
    Dirix, L. Y.
    Romieu, G.
    Chan, A.
    Pivot, X.
    Tomczak, P.
    Provencher, L.
    Cortes, J.
    Delmar, P. R.
    Scherer, S. J.
    BRITISH JOURNAL OF CANCER, 2013, 108 (05) : 1052 - 1060
  • [28] Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
    D W Miles
    S L de Haas
    L Y Dirix
    G Romieu
    A Chan
    X Pivot
    P Tomczak
    L Provencher
    J Cortés
    P R Delmar
    S J Scherer
    British Journal of Cancer, 2013, 108 : 1052 - 1060
  • [29] Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial
    Lang, I.
    Inbar, M.
    Steger, G.
    Greil, R.
    Zvirbule, Z.
    Beslija, S.
    Kahan, Z.
    Taskova, V.
    Kaufmann, B.
    Zielinski, C. C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 277 - 278
  • [30] Health economic evaluation of: Bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced breast cancer: A multicenter, randomized phase III trial - SAKK 24/0
    Matter-Walstra, Klazien W.
    Bigler, Martin
    Schwenkglenks, Matthias
    Bertschi, Daniela
    Brechbuehl, Joerg
    Hasler-Strub, Ursula
    von Moos, Roger
    Mueller, Andreas
    Winterhalder, Ralph
    Rochlitz, Christoph
    CANCER RESEARCH, 2015, 75
12345